. Effect of paclitaxel on the viability of ovarian cancer cell lines measured by MTT assay. Ovarian cancer (A) HEY and (B) TOV21G cell lines were treated with paclitaxel concentration ranging from 0.05-1 µg/mL and 0.0005-0.05 µg/mL respectively for 48 h before analysis by MTT assay. The graph represents four independent experiments performed in triplicate. Results are expressed as the percentage of the average OD reading relative to untreated cells ± SEM. Significance is indicated by
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